معرفی
Donald Kirsch is an Adjunct Lecturer in Biological Sciences at Columbia University and a pharmaceutical-industry consultant with nearly 40 years of drug-discovery experience at Squibb, Cyanamid, Wyeth and Cambria. He previously taught biotechnology at Harvard Extension School and has published over 50 papers, holds 27 drug-related patents, served 30 years on NIH study sections and secured >$6 million in research grants.
Education:
- AB in Biochemistry – Rutgers College
- PhD in Molecular Biology – Princeton University
- Postdoctoral training in Pharmacology – Robert Wood Johnson Medical School
- Genetics studies – Cold Spring Harbor Laboratory
- Engineering Management Certificate – Stanford Business School
Research & Industry Focus:
Kirsch’s career spans anti-infective, neuropsychiatric and neurodegenerative drug discovery. His laboratories developed high-throughput receptor–ligand matching technologies, advanced ALS drug candidates into clinical trials, and contributed molecular-genetic tools widely used in pharma R&D.
Publication Trends:
Recent works emphasize translational perspectives on pharmaceutical innovation, entrepreneurship and decision analytics, while earlier papers detail mechanistic studies in neuroprotection and natural-product antimicrobials, illustrating a trajectory from bench science to strategic drug-development science.
Professional Service:
- 30-year standing member of NIH study sections
- Journal reviewer for multiple pharmacology & biotechnology journals
- Consultant to biotechnology and pharmaceutical companies
At Columbia he brings this extensive industry insight to classroom instruction and student mentoring in modern drug discovery and biotechnology entrepreneurship.
